Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: A population-based, propensity score-adjusted trend analysis

Annals of Surgery

Volumn 262, Issue 1, 2015, Pages 112-120

  Tarantino, Ignazio ^a,b   Warschkow, Rene ^a,b   Worni, Mathias ^c,d   Cerny, Thomas ^a   Ulrich, Alexis ^b   Schmied, Bruno M ^a   Güller, Ulrich ^a,c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Incurable; Metastases; Metastatic colorectal cancer; Palliative resection

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; ICD-O-3; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROPENSITY SCORE; SEX DIFFERENCE; SYSTEMIC THERAPY; AGED; CANCER REGISTRY; COLORECTAL NEOPLASMS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; SURVIVAL; TRENDS; UNITED STATES;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84939419890     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000860     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Longo WE, Virgo KS, Johnson FE, et al. Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum. 2000;43:83-91.
3. Makela J, Haukipuro K, Laitinen S, et al. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33:846-850.
4. Legendre H, Vanhuyse F, Caroli-Bosc FX, et al. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol. 2001;27:364-367.
5. Sarela AI, Guthrie JA, Seymour MT, et al. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88:1352-1356.
6. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568-573.
7. Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6:651-657.
8. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379-3384.
9. Group NGTAT. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10:904-911.
10. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 2012;8:CD008997.
11. Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis. 2008;23:559-568.
12. National Cancer Institute. Surveillance epidemiology and end results. Available at http://seer.cancer.gov. Accessed May 31, 2013.
13. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control: a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14:175-193.
14. Fritz A, Percy C, Jack A, et al. International Classification of Disease for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-516.
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
17. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
18. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82:387-394.
19. Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Statist. 2006;15:609-627.
20. Ho DE, Imai K, King G, et al. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1-28.
21. Ishwaran H, Kogalur UB, Blackstone EH, et al. Random survival forests. Ann App Statist. 2008;2:841-860.
22. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
23. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
24. Rahbari NN, Lordick F, Fink C, et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS: a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer. 2012;12:142.
25. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637-645.
26. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22:3475-3484.
27. Engstrom PF, Arnoletti JP, Benson AB, III, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009;7:838-881.
28. Engstrom PF, Arnoletti JP, Benson AB, III, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009;7:778-831.
29. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
30. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
31. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl JMed. 2009;360:1408-1417.